PBR Nachrichten

 

It is a gamma-secretase modulator being developed as a potent once-daily oral therapy for the treatment and potential prevention of AD. According to the company, existing therapies approved The post Acta Pharmaceuticals raises $24m for Alzheimer's therapies appeared first on Pharmaceutical Business review....

The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies. Under the terms of the agreement, Mayo The post Transcripta Bio, Mayo Clinic join force on ALS therapies appeared first on Pharmaceutical Business review....

The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will analyse clinical The post QCi and INmune Bio partner to study XPro in Alzheimer's appeared first on Pharmaceutical Business review....

Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive an upfront The post Alentis and PinotBio partner to develop claudin-1 oncology ADCs appeared first on Pharmaceutical Business review....

The partnership focuses on biologics quality control as well as viral and release testing under current good manufacturing practice (cGMP) standards. Magellan recently completed Phase I/II clinical studies The post Charles River partners with Magellan Stem Cells on cell therapy appeared first on Pharmaceutical Business review....

Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. Pfizer will take full responsibility for subsequent The post Pfizer partners with Enodia Therapeutics in $500m drug deal appeared first on Pharmaceutical Business review....

The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci). GenSci holds exclusive Chinese commercial rights to Camcevi across all existing and The post China's NMPA clears Foresee's Camcevi 42 mg for prostate cancer appeared first on Pharmaceutical Business review....

The planned facility will focus on the development, validation, and adoption of new approach methodologies (NAMs). These laboratory, computational, and data-oriented methods are designed to mirror human biology The post Southern Research secures NIH funding for drug testing hub appeared first on Pharmaceutical Business review....

This oral medication is indicated for patients whose infections do not respond, with or without documented resistance, to standard antiviral therapies including acyclovir, famciclovir, or valacyclovir. The company The post FDA approves Asahi Kasei's Hovilpri for refractory HSV appeared first on Pharmaceutical Business review....

Under the terms of the agreement, the two companies will direct qualified customer opportunities to the other across the development pipeline. A joint governance structure will oversee the The post Perceptive, Nucleus partner to support radiopharmaceutical development appeared first on Pharmaceutical Business review....

The purpose-built 10,000ft² site is fully operational and produces materials to support developers working on cell therapies globally. The facility features two International Organization for Standardization-7 (ISO-7) cleanrooms The post Bio-Techne opens GMP small molecule facility in Bristol, UK appeared first on Pharmaceutical Business review....

The transaction grants Ono exclusive development and commercialisation rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 across the Association of Southeast Asian Nations (ASEAN) countries, Taiwan, South Korea, The post Biohaven partners with Ono in $100m IgG degrader deal appeared first on Pharmaceutical Business review....

This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment. The regulatory decision introduces an oral The post FDA approves Pfizer's Tukysa regimen for metastatic breast cancer appeared first on Pharmaceutical Business review....

The initiative represents the first time 10x Genomics has widened its clinical research scope past solid tumours to include haematologic malignancies. Under the partnership, the organisations will carry The post 10x Genomics and Fred Hutch partner on cancer technologies appeared first on Pharmaceutical Business review....

The financing arrangement extends the biotechnology company's projected operational cash runway into the third quarter of 2028 when combined with existing reserves, with further drawdowns potentially extending funding The post Rocket receives $150m credit facility to advance cardiovascular portfolio appeared first on Pharmaceutical Business review....

The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead's ongoing development and operational processes. The joint work is intended The post Gilead Sciences signs five-year DevOps agreement with Cognizant appeared first on Pharmaceutical Business review....

Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply The post Pacira partners with Molteni for Exparel commercialisation appeared first on Pharmaceutical Business review....

The 18-storey, 570,000ft² facility at 290 Binney Street features ten floors of interconnecting laboratories equipped with continuous automation, robotics, and agentic AI. Combined with the company's genomic medicine The post AstraZeneca opens new R&D centre in Cambridge, US appeared first on Pharmaceutical Business review....

Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose. The regulatory decision is The post FDA approves expanded indication for Lilly's Jaypirca appeared first on Pharmaceutical Business review....

The facility will be constructed in the New Albany International Business Park. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and The post Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US appeared first on Pharmaceutical Business review....